Table 2.
Demographic, Cardiovascular, and Clinical Characteristics of Statin Naïve Patients With Myocardial Infarction on Admission, According to Statin Use
| Group | Very Early Start, Group A, (n = 850) | No Very Early Start, Group B (n = 422) | P Value |
|---|---|---|---|
| Age, y | 62 (13) | 67 (14) | <0.001 |
| Women, % | 26.7 | 31 | 0.001 |
| STEMI, % | 57 | 54 | <0.001 |
| Hypertension, % | 55.5 | 60 | <0.001 |
| Hyperlipidemia, % | 48 | 40 | <0.001 |
| Diabetes mellitus, % | 21 | 24 | 0.008 |
| CKD, % | 0.2 | 0.2 | 0.2 |
| CDFH, % | 20.5 | 17 | 0.1 |
| Smoking, % | 37 | 28 | <0.001 |
| Previous MI, % | 10 | 15 | <0.001 |
| Previous heart failure, % | 5.5 | 3 | <0.001 |
| Thrombolysis, % | 4 | 3 | 0.7 |
| 1° PCI, % | 30 | 25 | 0.002 |
| SAP on admission, mm Hg | 138 (26) | 135 (29) | 0.01 |
| HR, bpm | 79 (18) | 82 (19) | 0.001 |
| Killip >1, % | 17 | 33 | 0.01 |
| Peak CK, U/L | 1572 (1981) | 1492 (1695) | <0.001 |
| Plasma glucose, mg/dL | 146 (66) | 153 (79) | 0.04 |
| Total cholesterol, mg/dL | 208 (46) | 183 (43) | <0.001 |
| HDL‐C, mg/dL | 46 (22) | 47 (37) | 0.1 |
| LDL‐C, mg/dL | 125 (53) | 105 (37) | <0.001 |
| Triglycerides, mg/dL | 190 (133) | 186 (43) | 0.05 |
| VT‐VF, % | 1 | 0.2 | 0.3 |
| Reinfarction, % | 0.2 | 0.4 | 0.5 |
| Heart failure, % | 5 | 11 | <0.001 |
| Mortality, % | 1.8 | 8.5 | <0.001 |
Abbreviations: CDFH, cardiovascular disease family history; CK, creatine kinase; CKD, chronic kidney disease; HDL‐C, high‐density lipoprotein cholesterol; HR, heart rate; LDL‐C, low‐density lipoprotein cholesterol; MI, myocardial infarction; PCI, percutaneous coronary intervention; SAP, systemic arterial pressure; STEMI, ST‐segment elevation myocardial infarction; VF, ventricular fibrillation; VT, ventricular tachycardia.
P value is for the comparison between group A and group B. Data are presented as mean (SD) except where indicated otherwise. Very early start was defined as initiation of statins within the first 24 hours after MI.